Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
331 stopped studies mapped to WHO Grade 4 Glioma and descendants · 90% state a reason
Over the 331 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04051047 | Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma | Early Phase 1 | withdrawn | Aug 9, 2019 | University of Michigan Rogel Cancer Center | Withdrawn by Principal Investigator | Investigator |
| NCT03843814 | Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma | N/A | terminated | Feb 18, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Imaging results were not sufficient or of good quality; therefore, we will not move further with… | Other (stated, no rule matched) |
| NCT00984438 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for… | Phase 1 / Phase 2 | withdrawn | Sep 25, 2009 | University of Cincinnati | No accrual | Enrollment / accrual |
| NCT00035373 | Eligibility Screening of Patients With Central Nervous System Tumors for the National… | — | terminated | May 3, 2002 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01182350 | Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | Phase 2 | terminated | Aug 16, 2010 | Karen D. Wright MD | Per design: Stop if fewer than 3 cohorts by molecular classification were with 10 participants or… | Enrollment / accrual |
| NCT03632317 | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With… | Phase 2 | withdrawn | Aug 15, 2018 | University of Michigan Rogel Cancer Center | low accrual | Enrollment / accrual |
| NCT03480867 | Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A…(PARADIGMA) | Phase 1 | withdrawn | Mar 29, 2018 | McGill University Health Centre/Research Institute of the McGill University Health Centre | competing study was opened by the surgeon after this trial was opened | Other (stated, no rule matched) |
| NCT03246113 | Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma | Phase 1 | terminated | Aug 11, 2017 | New York State Psychiatric Institute | Lack of subject interest due to study design | Other (stated, no rule matched) |
| NCT04002804 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With…(Dendr2) | Phase 1 | terminated | Jul 1, 2019 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Temozolomide does not favour immune response; secondary GBM to be excluded | Other (stated, no rule matched) |
| NCT00645385 | Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance…(Gliadel-MRS) | — | withdrawn | Mar 27, 2008 | Weill Medical College of Cornell University | not stated | Not stated |
| NCT02395692 | Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma | Phase 2 | terminated | Mar 24, 2015 | National Cancer Institute (NCI) | Pre-specified response criteria not met to proceed to next stage of study. | Other (stated, no rule matched) |
| NCT03403803 | Prognosis and Therapeutic Biomarkers for Glioblastoma Patients | — | terminated | Jan 19, 2018 | Baylor Research Institute | Were not able to meet enrollment goal due to inclusion/exclusion criteria | Enrollment / accrual |
| NCT03176160 | LITT Palliative Treatment for Patients With Malignant Gliomas | — | withdrawn | Jun 5, 2017 | Duke University | Failure to enroll | Enrollment / accrual |
| NCT01186406 | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed… | Phase 2 | terminated | Aug 23, 2010 | Duke University | Study ended early due to toxicity | Safety / toxicity |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With… | Phase 1 / Phase 2 | terminated | Jan 8, 2010 | Medical University of South Carolina | The study was terminated due to lack of adequate patient enrollment into trial. | Enrollment / accrual |
| NCT03293888 | Spectral Analysis Probe to Identify Glioblastoma Cells | — | terminated | Sep 26, 2017 | University of Oklahoma | PI Relocation | Other (stated, no rule matched) |
| NCT00734526 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly… | Phase 1 | terminated | Aug 14, 2008 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00895960 | Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | Phase 1 | terminated | May 11, 2009 | M.D. Anderson Cancer Center | Sponsor withdrew support; Study did not progress to Phase II. | Other (stated, no rule matched) |
| NCT02850744 | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of… | Phase 2 | terminated | Aug 1, 2016 | PIQUR Therapeutics AG | not stated | Not stated |
| NCT02062372 | Spatial Analysis and Validation of Glioblastoma on 7 T MRI | N/A | terminated | Feb 13, 2014 | Maastricht Radiation Oncology | Expectation that within the set time period insufficient patients will be included, so endpoints… | Other (stated, no rule matched) |
| NCT02176720 | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | Phase 1 | terminated | Jun 27, 2014 | The Methodist Hospital Research Institute | PI left HMRI | Investigator |
| NCT01103375 | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant… | Phase 1 | terminated | Apr 14, 2010 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT01575275 | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma… | Phase 2 | terminated | Apr 11, 2012 | Michael Vogelbaum, MD, PhD | Drugs unavailable | Other (stated, no rule matched) |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | Phase 2 | terminated | Apr 22, 2013 | Pediatric Brain Tumor Consortium | Due to several intracranial hemorrhages and recommendation by the PBTC DSMB. | Other (stated, no rule matched) |
| NCT02540135 | Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma | N/A | withdrawn | Sep 3, 2015 | University of Colorado, Denver | The investigators decided not to move forward with this study at this time. | Other (stated, no rule matched) |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | Phase 1 | withdrawn | Sep 7, 2017 | Center Trials & Treatment | Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that… | Enrollment / accrual |
| NCT01281982 | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | — | terminated | Jan 24, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01086345 | Radiosurgery Plus Bevacizumab in Glioblastoma | Early Phase 1 | terminated | Mar 15, 2010 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01234805 | Yoga Therapy in Treating Patients With Malignant Brain Tumors | N/A | terminated | Nov 4, 2010 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT00990496 | A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme… | Phase 1 | terminated | Oct 6, 2009 | Milton S. Hershey Medical Center | Accrual goals not met | Enrollment / accrual |
| NCT02227576 | Prevention of Thrombocytopenia in Glioblastoma Patients(PLATUM) | Phase 2 | terminated | Aug 28, 2014 | University Hospital, Lille | Study halted for efficacy following the results of the interim analysis provided for in the… | Efficacy / futility |
| NCT01702792 | Derivation of Tumor Specific Hybridomas | Phase 1 | terminated | Oct 8, 2012 | Dartmouth-Hitchcock Medical Center | Investigator is leaving Dartmouth | Investigator |
| NCT02365662 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced… | Phase 1 | terminated | Feb 19, 2015 | AbbVie | Safety | Safety / toxicity |
| NCT02654041 | Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients | Phase 2 | terminated | Jan 13, 2016 | Musli Thyropeutics Ltd. | Drug manufacturer no longer could supply for study | Drug supply |
| NCT02254954 | Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance… | Phase 1 | terminated | Oct 2, 2014 | Actelion | Sponsor decision due to low recruitment | Enrollment / accrual |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma… | Phase 2 | withdrawn | Feb 11, 2013 | University of Utah | Unable to get materials from GE, study not proceeding and never opened to accrual | Enrollment / accrual |
| NCT02047214 | Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed… | Phase 2 | terminated | Jan 28, 2014 | Cortice Biosciences, Inc. | Due to lack of clinical benefit in the 17 subjects enrolled in the trial to date | Efficacy / futility |
| NCT02590497 | Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed… | N/A | withdrawn | Oct 29, 2015 | Ohio State University Comprehensive Cancer Center | PI made decision | Other (stated, no rule matched) |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | Phase 2 | withdrawn | Feb 4, 2013 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma… | Phase 2 | withdrawn | Jan 28, 2015 | University of California, Davis | Poor Accrual | Enrollment / accrual |
| NCT01339039 | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | Phase 1 | terminated | Apr 20, 2011 | Patrick Y. Wen, MD | Low accrual rate | Enrollment / accrual |
| NCT02510950 | Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed… | Phase 1 | terminated | Jul 29, 2015 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT01666600 | NOA-12: BIBF1120 and R-RT in Glioblastoma | Phase 1 / Phase 2 | terminated | Aug 16, 2012 | Prof. Dr. Wolfgang Wick | Interim Analysis for Feasibility | Efficacy / futility |
| NCT02329795 | Image-derived Prediction of Response to Chemo-radiation in Glioblastoma(IDEPREG) | — | terminated | Jan 1, 2015 | Rigshospitalet, Denmark | Slow accrual | Enrollment / accrual |
| NCT01508117 | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | Phase 2 | terminated | Jan 11, 2012 | University of Cincinnati | transferred study sponsor | Other (stated, no rule matched) |
| NCT01526837 | Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma… | Phase 1 | terminated | Feb 6, 2012 | Brain & Spine Surgeons of New York | Investigators decision | Other (stated, no rule matched) |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | Phase 2 | withdrawn | Aug 10, 2011 | National Institute of Neurological Disorders and Stroke (NINDS) | not stated | Not stated |
| NCT00112866 | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive… | Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | due to poor accrual | Enrollment / accrual |
| NCT02039778 | Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma(STRONG) | N/A | terminated | Jan 20, 2014 | Beth Israel Medical Center | Poor Accural | Other (stated, no rule matched) |
| NCT01310855 | Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or… | Phase 2 | terminated | Mar 9, 2011 | University College, London | closed to recruitment early due to AstraZeneca not developing cediranib further | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 27, 2019source: clinicaltrials